ECSP045153A - Metodo y composición para aumentar la potencia de un analgésico de narcotico. - Google Patents

Metodo y composición para aumentar la potencia de un analgésico de narcotico.

Info

Publication number
ECSP045153A
ECSP045153A EC2004005153A ECSP045153A ECSP045153A EC SP045153 A ECSP045153 A EC SP045153A EC 2004005153 A EC2004005153 A EC 2004005153A EC SP045153 A ECSP045153 A EC SP045153A EC SP045153 A ECSP045153 A EC SP045153A
Authority
EC
Ecuador
Prior art keywords
narcotic
composition
analgest
increase
power
Prior art date
Application number
EC2004005153A
Other languages
English (en)
Inventor
Anil Gulati
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of ECSP045153A publication Critical patent/ECSP045153A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones y métodos para el tratamiento del dolor y la reducción o reversión de la tolerancia que los analgésicos de narcóticos están divulgados. La composición y método utiliza un analgésico de narcótico y un antagonista de endotelin como agentes activos para tratar del dolor en los mamíferos, incluyendo los humanos.
EC2004005153A 2001-11-27 2004-06-15 Metodo y composición para aumentar la potencia de un analgésico de narcotico. ECSP045153A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33359901P 2001-11-27 2001-11-27

Publications (1)

Publication Number Publication Date
ECSP045153A true ECSP045153A (es) 2004-08-27

Family

ID=23303472

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005153A ECSP045153A (es) 2001-11-27 2004-06-15 Metodo y composición para aumentar la potencia de un analgésico de narcotico.

Country Status (14)

Country Link
US (3) US7973064B2 (es)
EP (1) EP1448233A2 (es)
JP (1) JP2005513033A (es)
CN (1) CN1646166A (es)
AU (1) AU2002348224A1 (es)
BR (1) BR0214481A (es)
CA (1) CA2464768C (es)
CO (1) CO5590940A2 (es)
EA (1) EA200400734A1 (es)
EC (1) ECSP045153A (es)
MX (1) MXPA04005003A (es)
NO (1) NO20042612L (es)
WO (1) WO2003045434A2 (es)
ZA (1) ZA200403162B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070300258A1 (en) * 2001-01-29 2007-12-27 O'connor Daniel Methods and systems for providing media assets over a network
DE60143671D1 (de) * 2001-06-07 2011-01-27 Sang Christine Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor-antagonists
TWI232102B (en) * 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
EP2060259B1 (en) 2001-11-01 2010-01-20 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US7351692B2 (en) 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
US8217010B2 (en) 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
CN1729012B (zh) 2002-10-24 2013-05-22 伊利诺伊大学评议会 治疗实体瘤的组合物
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
EP1976549A4 (en) * 2005-09-09 2010-05-19 Chicago Labs Inc ENDOTHELIN RECEPTORS FOR WEANING MORPHINE
EP2314289A1 (en) * 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
ES2541657T3 (es) 2006-08-31 2015-07-23 Spectrum Pharmaceuticals, Inc. Sensibilización de células tumorales a terapia de radiación a través de la administración de agonistas de endotelina
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
WO2009015917A2 (en) * 2007-05-14 2009-02-05 F. Hoffmann-La Roche Ag Dihydroquinone and dihydronaphthridine inhibitors of jnk
US20090143426A1 (en) * 2007-12-04 2009-06-04 Ralph Anthony Stephani Synthesis of 1,3,6-trisubstituted-2-carboxyquinol-4-ones as selective ET A antagonists and their use as medicaments
PL2424529T3 (pl) * 2009-04-30 2017-06-30 Midwestern University Nowe postępowania terapeutyczne z zastosowaniem centakwiny
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP3019242B1 (en) 2013-07-08 2020-08-19 Midwestern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist
CN112469474A (zh) 2018-05-03 2021-03-09 美国中西部大学 出血和centhaquin引起的复苏后内皮素受体的变化
CN112569238A (zh) * 2019-09-30 2021-03-30 武汉大学 伊马替尼及其衍生物与镇痛药联合用药或复方制剂在治疗疼痛中的应用
CN114796448A (zh) * 2022-05-06 2022-07-29 延安大学 可乐定与Gap26在制备镇痛药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
JPH08139146A (ja) * 1994-11-14 1996-05-31 Shin Etsu Handotai Co Ltd 半導体表面のライフタイム評価方法
RU2180852C2 (ru) 1994-12-12 2002-03-27 Омерос Медикл Системс, Инк. Ингибирующий раствор и способ подавления боли, воспаления или спазма
US6673832B1 (en) * 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
EP1289558A2 (en) 2000-05-31 2003-03-12 Warner-Lambert Company Llc Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US6573285B2 (en) * 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
US20030232787A1 (en) * 2001-05-08 2003-12-18 Dooley David James Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic

Also Published As

Publication number Publication date
MXPA04005003A (es) 2004-08-11
JP2005513033A (ja) 2005-05-12
EA200400734A1 (ru) 2004-12-30
NO20042612L (no) 2004-06-22
CA2464768A1 (en) 2003-06-05
US8114896B2 (en) 2012-02-14
WO2003045434A2 (en) 2003-06-05
EP1448233A2 (en) 2004-08-25
US7973064B2 (en) 2011-07-05
WO2003045434A3 (en) 2003-09-25
US8410148B2 (en) 2013-04-02
CO5590940A2 (es) 2005-12-30
ZA200403162B (en) 2005-01-26
US20100113396A1 (en) 2010-05-06
US20030100507A1 (en) 2003-05-29
CN1646166A (zh) 2005-07-27
US20100311665A1 (en) 2010-12-09
AU2002348224A1 (en) 2003-06-10
BR0214481A (pt) 2004-09-14
CA2464768C (en) 2009-12-29

Similar Documents

Publication Publication Date Title
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
NI200500087A (es) Derivados 4-tetrazolyl-4 fenilpiperidina para el tratamiento del dolor
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
PT1411908E (pt) Tratamento de infeccoes da unha com no
CY1107424T1 (el) Χρηση ενος αναστολεα ibat για τη θεραπευτικη αντιμετωπιση η προφυλαξη απο δυσκοιλιοτητα
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
CY1111177T1 (el) Ενωση φαινοθειαζινιου για επουλωση τραυματων
MXPA04001876A (es) Uso de fucanos en el tratamiento de adhesiones, artritis y psoriasis.
EP1605956A4 (en) ADMINISTRATION OF CAPSAICINOIDS
CU23213A3 (es) Difenilureas sustituidas con omega-carboxiarilo como inhibidores de raf quinasa
CY1107242T1 (el) Μυριστικο κητυλιο και παλμικο κητυλιο για τη θεραπεια του εκζεματος ή/και της ψωριασης
AR044039A1 (es) Combinaciones antineoplasicas
CO5050298A1 (es) Metodo y composicion para tratar impotencia
ECSP066575A (es) Antagonistas del receptor b1 de bradiquinina
CY1109031T1 (el) Τριαζασπιρο ενωσεις χρησιμες για την αντιμετωπιση ή προληψη πονου
EP1631267A4 (en) METHOD FOR THE TREATMENT OF DISORDERS WITH HSP90-INHIBITING AGENTS COMBINED WITH ANTIMETABOLITES
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
DE602004014787D1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
WO2004071413A3 (en) Method and composition for potentiating an opiate analgesic
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
SE0004101D0 (sv) New use
AR015956A1 (es) Composiciones de citoquinas oromucosales y usos de las mismas
IS4847A (is) Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni
AR019327A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada